Cinven sells AMCo to Concordia Healthcare

On October 21, 2015, Cinven completed its sale of Amdipharm Mercury Limited (AMCo) to Concordia Healthcare Corp., (Concordia) for an enterprise value of US$3.5 billion, through a combination of cash, common shares of Concordia, and a maximum performance-based earnout of US$220 million over the next 12 months, from October 1, 2015.

Concordia financed the cash portion of the purchase price for AMCo through a combination of US$2.8 billion of debt financings, gross proceeds of US$520 million raised from the company's public equity offering, and cash on hand. The capital was also utilized to refinance certain Concordia and AMCo debt.

AMCo is a rapidly growing international pharmaceutical company, committed to bringing its portfolio of niche medicines to patients in more than 100 countries.

Concordia is a diverse healthcare company focused on legacy pharmaceutical products and orphan drugs.

Cinven is a leading European private equity firm.

Further information can be found on Concordia's website, as well as newswire.ca.